Qun-ling R. Zhang

130 Dong An Road
Xuhui, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome.

Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome.

Journal: Science translational medicine

Published: April 01, 2026

Zanubrutinib potentiates polatuzumab vedotin efficacy in DLBCL with concurrent CD79b upregulation.

Zanubrutinib potentiates polatuzumab vedotin efficacy in DLBCL with concurrent CD79b upregulation.

Journal: Annals of hematology

Published: January 28, 2026

Lactate-induced miR-7-5p/TRIM33 reprograms metabolic flux to suppress tumor growth and viral reactivation.

Lactate-induced miR-7-5p/TRIM33 reprograms metabolic flux to suppress tumor growth and viral reactivation.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: August 13, 2025

PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study.

PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study.

Journal: Leukemia & lymphoma

Published: January 05, 2025

Report of six cases with mast cell leukemia and a literature review

Report of six cases with mast cell leukemia and a literature review

Journal: Zhonghua nei ke za zhi

Published: October 07, 2024

Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results.

Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results.

Journal: The oncologist

Published: January 04, 2024

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment.

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment.

Journal: Blood

Published: January 03, 2023

Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China.

Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China.

Journal: BMC medicine

Published: August 14, 2022

Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.

Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.

Journal: Leukemia

Published: April 30, 2022

Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases.

Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 06, 2022

Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes.

Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes.

Journal: Cell reports. Medicine

Published: February 16, 2022

Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.

Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.

Journal: International journal of hematology

Published: January 27, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026